NORTHVALE, N.J., Aug. 3, 2017 /PRNewswire/ -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) is in development of two technologies for the tinnitus field. These new developments were featured in the most recent edition of OneMedMarket's newsletter "The Sentinel – Breakthroughs in Health & Technology" in its Top Story entitled "Tinnitus: When the World is Too Loud" which is available at the following link: http://www.onemednews.com/2017/07/31/tinnitus-world-loud/
Both ADMT's technologies for the tinnitus marketplace, Tinnitus Shield™ and Aurex-3®, are described in the Top Story article. Tinnitus is a hearing condition commonly known as "ringing in the ears." The American Tinnitus Association estimates there are up to 50 million tinnitus sufferers in the U.S. and some 250 million worldwide.
As previously announced, the Tinnitus Shield™ technology is a specialized, patent-pending hearing protection device which can help to avoid damaging levels of sound which have been known to cause or worsen tinnitus conditions. The Aurex-3® is a patented, therapeutic electronic medical device which is intended to be used for the treatment and control of tinnitus. ADMT expects Tinnitus Shield™ to be commercially available within the next 60 days and the Aurex-3® later this fiscal year. More information is available at aurex3.com.
The Sentinel is an e-newsletter distributed to healthcare executives and investors, and is available at the OneMedMarket website. OneMedMarket is a New York-based life science and healthcare research and investor communications firm providing business development services to emerging growth companies and identifying investment opportunities for healthcare investors.
About ADMT ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services and Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, such as rapid 3-D solid prototyping, precision instrumentation and specialized software and peripherals, for the research, development and commercialization of diversified technologies. Additional information is available at the Company's websites - admtronics.com and concepttoquantity.com.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Advertisement
Both ADMT's technologies for the tinnitus marketplace, Tinnitus Shield™ and Aurex-3®, are described in the Top Story article. Tinnitus is a hearing condition commonly known as "ringing in the ears." The American Tinnitus Association estimates there are up to 50 million tinnitus sufferers in the U.S. and some 250 million worldwide.
Advertisement
As previously announced, the Tinnitus Shield™ technology is a specialized, patent-pending hearing protection device which can help to avoid damaging levels of sound which have been known to cause or worsen tinnitus conditions. The Aurex-3® is a patented, therapeutic electronic medical device which is intended to be used for the treatment and control of tinnitus. ADMT expects Tinnitus Shield™ to be commercially available within the next 60 days and the Aurex-3® later this fiscal year. More information is available at aurex3.com.
The Sentinel is an e-newsletter distributed to healthcare executives and investors, and is available at the OneMedMarket website. OneMedMarket is a New York-based life science and healthcare research and investor communications firm providing business development services to emerging growth companies and identifying investment opportunities for healthcare investors.
About ADMT ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services and Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, such as rapid 3-D solid prototyping, precision instrumentation and specialized software and peripherals, for the research, development and commercialization of diversified technologies. Additional information is available at the Company's websites - admtronics.com and concepttoquantity.com.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
View original content:http://www.prnewswire.com/news-releases/adm-tronics-new-tinnitus-technologies-featured-in-top-story-in-onemedmarket-sentinel-newsletter-300499150.html
SOURCE ADM Tronics Unlimited, Inc.
